news
Oncology trials are taking longer
4 November 2014 | By KMR Group
KMR Group, a leader in analyzing R&D performance data for the biopharmaceutical industry, has recently assessed the duration of oncology trials...
List view / Grid view
Oncology
news
New Oncology and Gustave Roussy announce collaboration on genetic testing
14 October 2014 | By New Oncology
New Oncology announced that it has entered into a collaboration agreement with Gustave Roussy Cancer Campus, Paris...
news
Merck Serono to collaborate with The Institute of Cancer Research, London, and Wellcome Trust to co-develop anti-cancer drugs
8 October 2014 | By The Wellcome Trust, The Institute of Cancer Research & Merck Serono
Merck Serono, The Institute of Cancer Research, and the Wellcome Trust, London, have announced a co-development and license agreement building on two independent research programs at both the ICR and Merck Serono to identify inhibitors of tankyrase, an enzyme of the poly (ADP-ribose) polymerase family...
news
Bristol-Myers Squibb and MD Anderson Cancer Center announce novel research collaboration in immuno-oncology focused on leukemia and hematologic malignancies
6 October 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and The University of Texas MD Anderson Cancer Center announced a novel clinical research collaboration to evaluate multiple immunotherapies...
news
CleveXel Pharma to license two new oncology patents from SATT Sud Est
6 October 2014 | By CleveXel Pharma
They will address the treatment of bone marrow cancers and the diagnosis of patients who are resistant to standard treatments...
news
Helsinn announces that pivotal Phase III trial data for Anamorelin in ROMANA 1 and 2 studies in non-small cell lung cancer patients with anorexia-cachexia will be presented at the 38th European Society for Medical Oncology (ESMO) Congress in 2014
25 September 2014 | By Helsinn
Helsinn Group announces that Phase III data from the largest trial program of its kind to date in anamorelin, a novel, once-daily ghrelin receptor agonist in development for cancer-anorexia-cachexia (CACS) in non-small cell lung cancer will be presented at the 38th European Society for Medical Oncology Congress...
news
European Commission grants marketing authorization for Gilead’s Zydelig® (Idelalisib) for the treatment of chronic lymphocytic leukemia and follicular lymphoma
22 September 2014 | By Gilead Sciences
Gilead Sciences, Inc. announced that the European Commission has granted marketing authorization for Zydelig® (idelalisib), 150 mg tablets, a first-in-class oral treatment for two incurable blood cancers - chronic lymphocytic leukemia and follicular lymphoma...
news
Ample room available for novel products in metastatic prostate cancer treatment market, says GlobalData Analyst
18 September 2014 | By Globaldata
Despite numerous product launches in the metastatic castration-resistant prostate cancer treatment market since 2010, ample opportunity still exists for drug developers to claim their stake in the arena...
news
Roche to present latest oncology advances during ESMO 2014 Congress
17 September 2014 | By Roche
Roche announced that important new data from its established and pipeline medicine portfolio will be presented during the European Society for Medical Oncology (ESMO) 2014 Congress from 26-30 September in Madrid, Spain...
news
Lilly announces CYRAMZA™ Phase III second-line colorectal cancer trial meets primary endpoint of overall survival
12 September 2014 | By Eli Lilly and Company
Eli Lilly and Company announced that the RAISE trial, a Phase III study of ramucirumab (CYRAMZA™) in combination with chemotherapy in patients with metastatic colorectal cancer (mCRC), met its primary endpoint of overall survival...
news
Merck to present new data in five tumor types from studies svaluating pembrolizumab, the company’s investigational anti-PD-1 antibody, at ESMO 2014
3 September 2014 | By Merck
Merck announced the presentation of data from ongoing clinical trials evaluating the anti-tumor activity of pembrolizumab, the company’s investigational anti-PD-1 antibody...
news
AstraZeneca and Roche announce partnership to develop companion diagnostic test for AZD9291
28 July 2014 | By AstraZeneca
AstraZeneca announced it has entered into collaboration with Roche to develop a plasma-based companion diagnostic test to support AZD9291...
news
Johnson & Johnson Innovation announces immuno-oncology lung cancer collaboration with the Dana-Farber Cancer Institute’s Belfer Institute for Applied Cancer Science
25 June 2014 | By Johnson & Johnson
Johnson & Johnson Innovation, Boston and Janssen Biotech, Inc. announced a three-year immuno-oncology lung cancer collaboration with the Dana-Farber Cancer Institute...
news
Amgen presents new data on talimogene laherparepvec as single agent and combination therapy in metastatic melanoma at ASCO
3 June 2014 | By Amgen
Amgen announced new data from two key clinical trials that support the potential of talimogene laherparepvec, a novel, investigational oncolytic immunotherapy, as both a single agent and as part of a combination regimen in patients with metastatic melanoma...
news
Major study reveals new ways to classify cancer
27 September 2013 | By Cancer Research UK
A US-led initiative to map the molecular similarities and differences of thousands of tumours has revealed new ways to classify cancer...
